KR20240167654A - 암의 치료를 위한 gdc-6036 및 gdc-0077을 포함하는 병용 요법 - Google Patents

암의 치료를 위한 gdc-6036 및 gdc-0077을 포함하는 병용 요법 Download PDF

Info

Publication number
KR20240167654A
KR20240167654A KR1020247032867A KR20247032867A KR20240167654A KR 20240167654 A KR20240167654 A KR 20240167654A KR 1020247032867 A KR1020247032867 A KR 1020247032867A KR 20247032867 A KR20247032867 A KR 20247032867A KR 20240167654 A KR20240167654 A KR 20240167654A
Authority
KR
South Korea
Prior art keywords
gdc
administered
pharmaceutically acceptable
acceptable salt
inabolisib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032867A
Other languages
English (en)
Korean (ko)
Inventor
마크 앤드류 머챈트
제니퍼 리 슈츠만
젠 시
춘얀 송
니케쉬 비제이 다리아
스테파니 로이어 주
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20240167654A publication Critical patent/KR20240167654A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247032867A 2022-04-06 2023-04-04 암의 치료를 위한 gdc-6036 및 gdc-0077을 포함하는 병용 요법 Pending KR20240167654A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263328149P 2022-04-06 2022-04-06
US63/328,149 2022-04-06
PCT/US2023/017455 WO2023196329A1 (en) 2022-04-06 2023-04-04 Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer

Publications (1)

Publication Number Publication Date
KR20240167654A true KR20240167654A (ko) 2024-11-27

Family

ID=86286527

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032867A Pending KR20240167654A (ko) 2022-04-06 2023-04-04 암의 치료를 위한 gdc-6036 및 gdc-0077을 포함하는 병용 요법

Country Status (13)

Country Link
US (2) US12383557B2 (cg-RX-API-DMAC7.html)
EP (1) EP4504202B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511352A (cg-RX-API-DMAC7.html)
KR (1) KR20240167654A (cg-RX-API-DMAC7.html)
CN (1) CN119013026A (cg-RX-API-DMAC7.html)
AU (1) AU2023249068A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255718A1 (cg-RX-API-DMAC7.html)
ES (1) ES3067080T3 (cg-RX-API-DMAC7.html)
IL (1) IL315250A (cg-RX-API-DMAC7.html)
MX (1) MX2024012230A (cg-RX-API-DMAC7.html)
PL (1) PL4504202T3 (cg-RX-API-DMAC7.html)
TW (1) TW202345846A (cg-RX-API-DMAC7.html)
WO (1) WO2023196329A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250000802A1 (en) * 2023-06-09 2025-01-02 Hoffmann-La Roche Inc. Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909173B (zh) 2015-07-02 2025-03-04 豪夫迈·罗氏有限公司 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
WO2020097537A2 (en) 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
TWI829003B (zh) 2020-08-12 2024-01-11 美商建南德克公司 喹唑啉化合物之合成
EP4243827A1 (en) 2020-11-13 2023-09-20 Genentech, Inc. Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
KR102975432B1 (ko) 2020-11-13 2026-06-10 제넨테크, 인크. 고형 종양 치료를 위한 krasg12c 억제제 및 vegf 억제제를 포함하는 방법 및 조성물
TWI895563B (zh) 2020-12-08 2025-09-01 美商建南德克公司 用於治療實性瘤之包含krasg12c抑制劑及egfr抑制劑之組成物及方法
AR128449A1 (es) 2022-02-07 2024-05-08 Genentech Inc Proceso para la síntesis de compuestos de quinazolina
CN118742544A (zh) 2022-02-07 2024-10-01 基因泰克公司 1-((s)-4-((r)-7-(6-氨基-4-甲基-3-(三氟甲基)吡啶-2-基)-6-氯-8-氟-2-(((s)-1-甲基吡咯烷-2-基)甲氧基)喹唑啉-4-基)-3-甲基哌嗪-1-基)丙-2-烯-1-酮的固体形式

Also Published As

Publication number Publication date
US12383557B2 (en) 2025-08-12
EP4504202A1 (en) 2025-02-12
US20230321102A1 (en) 2023-10-12
IL315250A (en) 2024-10-01
CN119013026A (zh) 2024-11-22
AU2023249068A1 (en) 2024-09-05
PL4504202T3 (pl) 2026-05-04
ES3067080T3 (en) 2026-05-19
TW202345846A (zh) 2023-12-01
CA3255718A1 (en) 2023-10-12
JP2025511352A (ja) 2025-04-15
US20260053802A1 (en) 2026-02-26
MX2024012230A (es) 2024-11-08
EP4504202B1 (en) 2026-02-04
WO2023196329A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US20200246338A1 (en) Combination therapy
WO2017013160A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US20220280523A1 (en) Combination of pi3k inhibitor and c-met inhibitor
AU2017275650B2 (en) Pharmaceutical combinations
US20140178366A1 (en) Preselection of subjects for therapeutic treatment based on hypoxic status
US20140024030A1 (en) Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status
JP2017503842A (ja) 癌治療のためのアピリモド(apilimod)組成物
US12409178B2 (en) Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors
US20260053802A1 (en) TREATMENT OF CANCER USING COMBINATION THERAPIES COMPRISING GDC-6036 and GDC-0077
JP2014530181A (ja) PI3Kβ阻害剤ならびにMEKおよびRAF阻害剤を含むMAPK経路阻害剤を使用する、癌を処置するための組成物および方法
TW201306837A (zh) 使用pi3k抑制劑及mek抑制劑用於治療癌症之組成物及方法
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
US20260027117A1 (en) Methods of treating small cell lung cancer
KR20230116899A (ko) 고형 종양 치료를 위한 krasg12c 억제제 및 egfr-억제제를포함하는 방법 및 조성물
HK40118757A (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
US20250268900A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
CA2869152A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
RU2784869C1 (ru) Чиаураниб для лечения мелкоклеточного рака легкого
EA039396B1 (ru) Лечение рака молочной железы с тройным негативным фенотипом ингибиторами tor-киназы
TW201315471A (zh) 使用PI3Kβ抑制劑及包括MEK及RAF抑制劑之MAPK通道抑制劑之供治療癌症之組合物及方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000